SMARCA5 and neoplasm: As the Smarca5 loss was sensed in a mouse model by a) increased p53 levels and b) associated with DNA damage response (DDR), and c) activation of the p53 targets [1], very likely the tumor cells with DDR sensing defect would have a higher propensity to tolerate SMARCA5 level downregulation.